Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ScandiDos ABOSTO:SDOS 47 3-Year EBITDA Growth Rate is 43.30% as of Apr. 2026, which is 98% above its 10-year median of 21.85. GuruFocus rates OSTO:SDOS with a GF Score™ of 47/100 and a GF Value™ of kr1.13 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 690 Medical Devices & Instruments companies, ScandiDos AB ranks better than 84.78% on this metric.
During the past 12 months, ScandiDos AB's average EBITDA Per Share Growth Rate was -124.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 43.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of ScandiDos AB was 47.80% per year. The lowest was -10.80% per year. And the median was 21.85% per year.
ScandiDos AB (OSTO:SDOS) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
ScandiDos AB 3-Year EBITDA Growth Rate Related Terms
OSTO:SDOS vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, ScandiDos AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ScandiDos AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ScandiDos AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where ScandiDos AB's 3-Year EBITDA Growth Rate falls into.
ScandiDos AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 43.30% mean?
ScandiDos AB (OSTO:SDOS) has a 3-Year EBITDA Growth Rate of 43.30% as of Apr. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ScandiDos AB and its competitors. This is 98% above median its historical median of 21.85. According to the industry distribution chart, ScandiDos AB ranks #105 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 15.2%.
Is ScandiDos AB's 3-Year EBITDA Growth Rate too high?
ScandiDos AB's current 3-Year EBITDA Growth Rate of 43.30% is 98% above median its 10-year median of 21.85. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. ScandiDos AB's value of 43.30% is 428% above this industry median. Based on the distribution chart, ScandiDos AB ranks #105 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ScandiDos AB has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ScandiDos AB's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ScandiDos AB ranks #105 out of 690 companies for 3-Year EBITDA Growth Rate. This places ScandiDos AB in the top 15% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. ScandiDos AB's value of 43.30% is 428% above this benchmark. While the company's 10-year median is 21.85 vs. the industry median of 8.20, ScandiDos AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ScandiDos AB's current 3-Year EBITDA Growth Rate of 43.30% is 428% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ScandiDos AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ScandiDos AB's current 3-Year EBITDA Growth Rate is 43.30%, which is 98% above median its own 10-year median of 21.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ScandiDos AB stock overvalued right now?
Based on GuruFocus' analysis, ScandiDos AB (OSTO:SDOS) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.13, compared to a current price of kr0.87 — trading 23% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 43.30%, which is 98% above median its 10-year median of 21.85 and 428% above the Medical Devices & Instruments industry median of 8.20. ScandiDos AB's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For ScandiDos AB (OSTO:SDOS), the current 3-Year EBITDA Growth Rate is 43.30% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ScandiDos AB (OSTO:SDOS) Overvalued in 2026?
Based on GuruFocus' analysis, ScandiDos AB stock appears to be undervalued.
The current stock price of kr0.87 is trading 23% below its estimated GF Value™ of kr1.13.
GuruFocus considers ScandiDos AB to be Modestly Undervalued.
Key valuation signals for OSTO:SDOS:
3-Year EBITDA Growth Rate: 43.30% (98% above median its 10-year median of 21.85)
GF Value™: kr1.13 vs. price of kr0.87 (23% below fair value)
Industry Position: 428% above the Medical Devices & Instruments median (#105 of 690)
No single metric tells the full story. See the OSTO:SDOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ScandiDos AB is engaged in providing radiation therapy for cancer. Its product, Delta4 Phantom+, and its various hardware and software options are at the heart of everything ScandiDos does, from product development and production to marketing, sales, and customer support. With Delta4 HexaMotion ScandiDos has successfully developed a motion platform that recreates the movement of the tumor in six dimensions and independently simulates the patient's breathing movement.
47GF Score
Get the complete analysis for OSTO:SDOS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SDOS has been successfully added to your 
